Is It Ethical to Take People Off HIV Meds for Cure Research?

Cure studies typically require a temporary break in HIV treatment, often with little promise of a personal benefit to the participant.

By Benjamin Ryan

In recent years, researchers have firmly established that people living with HIV can best protect their health by starting antiretroviral (ARV) medications as early as possible in the course of their infection. From then on, it’s important to adhere well to the daily drug regimen indefinitely. Even structured breaks from ARVs—the so-called drug holidays that were once in vogue—were proved harmful in the mid-2000s.

So why are the investigators behind so many studies in the HIV research field these days experimenting with taking people off their ARVs for periods of time?

They do it in the name of finding a cure. Or if not a cure—meaning total eradication of HIV from the body—then some form of viral remission or post-treatment control of the virus without daily ARV treatment. Such outcomes may include a scenario in which HIV is still clearly present but the immune system suppresses the virus well on its own. Or perhaps the population of virus in the body has been so decimated it fails to bounce back, at least for an extended period. (In this article, the umbrella term “HIV cure” applies to research into prompting any such outcomes).

Analytical treatment interruptions (ATIs), as they are often known, are an integral facet of the kind of search-and-discovery work that characterizes HIV cure research in this early stage of the game. (The overall HIV cure research endeavor may stretch across decades, hopefully yielding progressive successes along the way.) Because a central goal of cure research is to allow people freedom from daily drugs, a primary reason scientists work ATIs into such studies is to analyze how the virus behaves in the absence of such suppressive medications.

Unfortunately, today’s cure studies typically cannot promise any major personal benefit to their participants. Rather, the hoped-for benefit is usually restricted to a contribution to greater scientific knowledge. And even though ATIs in these studies involve very close, rigorous monitoring of participants to mitigate risks, the risks—in particular long-term ones—may be unknown.

“Ultimately, this kind of research really relies on people being willing to take on some risk for the benefit of others,” says Seema Shah, JD, an associate professor of pediatrics at the University of Washington and faculty member in the Treuman Katz Center for Pediatric Bioethics. “That is ethically complex.”

Research into HIV-positive people’s reasons for wanting to participate in cure research has found that altruism is in fact a major motivating factor, which is a promising sign that cure studies will continue to find willing participants.

ATIs: Helping solve the mystery of the viral reservoir

Standard ARV treatment is highly effective at suppressing viral replication. However, the stubborn persistence of the viral reservoir keeps treatment from curing, or eradicating, the virus. While researchers are still hard at work characterizing just what makes up the reservoir, they’ve known since early on that HIV is able to harbor copies of itself below the radar of ARVs. The perseverance of these hidden stores means that when an individual stops his or her daily treatment, a once-undetectable viral load almost always bounces back up, typically within weeks.

A cornerstone of the reservoir is the collection of long-lived immune cells that are latently infected with HIV, meaning that they have virus integrated into their DNA but are not replicating, that is, not producing new copies of the virus. HIV treatment works only on replicating cells, meaning that ARVs cannot attack virus in latently infected cells, which may remain in a resting state for years before springing back to action and churning out viral copies.

Today’s HIV cure studies run a very wide gamut in their approaches. Some seek to shrink the size of the reservoir through a process known as “kick and kill,” waking up un-replicating cells and then attempting to destroy them. Others give individuals some sort of gene-based or antibody-based treatment intended to prime their body to better control the virus without daily drugs. There are also studies of people, both those who contracted HIV as adults and children born with the virus, who were treated very early in the course of their infection and who may as a result have a very small, or possibly even nonexistent, reservoir. These early-treated individuals may be able to go off their ARVs and spend considerable time—sometimes many years, as researchers have seen thus far in a handful of cases—without the reservoir prompting the viral load to rebound.

When it comes to studies that take participants off daily ARVs, researchers structure the research projects to analyze one of two factors: 1) the time until the virus rebounds; or 2) the level of equilibrium the virus ultimately reaches in the body after a rebound, known as the viral set point. Scientists hope to use data on individuals in these studies to help, for example, estimate the size of an individual’s reservoir. (A smaller reservoir likely means a longer time to rebound, likely because the chances are smaller that at any given time one long-lived, latently-infected cell will wake up and succeed in producing viable copies of virus). And very importantly, they are looking for biomarkers to use as the basis for tests that in the future could help predict whether an individual is likely to experience an extended period without a viral rebound after an ATI and how long that period is likely to last.

Studies that measure the time to viral rebound during an ATI expose participants to much less risk than the viral set point studies.
Steven Deeks, MD, a professor of medicine at the University of California, San Francisco and a major player in the HIV cure research field, says, “If someone’s willing to go through the rigors of careful monitoring, which means having viral loads tested two or three times a week, and willing to start antiretroviral therapy the minute the viral load goes to 51 copies, I think that then an interruption can be done pretty safely. The risks are really minimal. They’re not zero; there’s never zero risk.”

Jintanat Ananworanich, MD, PhD, who directs research in the HIV cure field in her capacity as the associate director for therapeutics research at the U.S. Military HIV Research Program, says that thanks to such close monitoring of participants in these time-to-rebound studies, “at least in the short term we do not see adverse events in terms of clinical symptoms.” She says that those under her care—she is researching ATIs among those who started HIV treatment very early—don’t experience a drop in their CD4 count and after they restart ARVs ultimately get their viral reservoir back to the size it was before the ATI. (Granted, tools for accurately measuring the reservoir are limited.)

“We’re learning a lot,” says Ananworanich of the benefits of using ATIs in cure research.
Regarding studies designed to look for the viral set point established during an ATI, Deeks says, “That’s where risks become much more substantial. But the knowledge gained is also much more substantial.”

These types of studies usually involve an experimental treatment crafted to prompt the immune system to control the virus on its own after the participant goes off ARVs. The ATI needs to extend long enough to allow the virus to surge, possibly up to a viral load in the tens of thousands, and for the immune system, buoyed by the experimental therapy, to bring it back down to an eventual viral set point. Such an extended period of a high viral load—these ATIs typically last about six weeks—introduces the possibility of the kind of flu-like symptoms associated with acute HIV infection. Additionally, during this period, CD4s may drop, and individuals become significantly infectious to their partners.

In fact, one individual in a recent vaccine trial that involved an ATI transmitted the virus to his partner during this time. According to Deeks, there is a movement afoot to add the practice of offering Truvada (tenofovir disoproxil fumarate/emtricitabine) as pre-exposure prophylaxis (PrEP) to the sexual partners of participants in studies involving ATIs.

Allowing the virus to replicate, particularly if for an extended period of several weeks, may raise health risks associated with the harmful chronic inflammation to which even fully suppressed HIV gives rise. Scientists believe chronic inflammation is a major contributor to the raised risk, most notably, of cardiovascular disease among those living with the virus. In theory, allowing for a greater level of inflammation during an ATI could, for example, lead to lasting damage in tissue-based immune cells in the gut or lymph nodes.

Then there’s always the risk that the virus could develop resistance to ARVs during an ATI, compromising the effectiveness of future daily treatment regimens. The virus of an individual who takes such a break in ARV treatment may also become less responsive to a future cure therapy.

Informed Consent

The point at which potential participants of medical studies are informed of all the potential associated risks and benefits—and sign on the dotted line if they agree to participate—presents a vital opportunity for researchers to ensure that HIV cure studies are conducted in the most ethical manner possible.

Unfortunately, according to Deeks, “The informed consent process is broken, in my opinion.” He criticizes the insistence of financial backers of HIV cure research on drafting consent forms that include everything plus the kitchen sink and run as long as 15 to 20 pages. “No one really reads those,” he says.

Deeks argues that a more ideal informed consent process involves drawn out, fully interactive communication between study investigators and potential participants. The ultimate goal is to make sure those considering enrolling in such research studies fully understand the risks, potential benefits as well as the benefits that are unlikely (such as an actual individual cure) to result from such participation. Fortunately, many cure study investigators do indeed engage in such careful and thoughtful dialogue to ensure that potential participants are fully informed before agreeing to participate.

Word choice regarding long-term research goals is also very important. Many researchers worry that even using the term “HIV cure” can inflate hopes and motivate participants in such trials to take on more risk than they would otherwise be comfortable with.
Potential participants of such studies who wrongly presume they may be cured “are not making a rational choice, balancing the potential risks and benefits,” says Richard Jefferys, Treatment Action Group’s cure research expert.

Keeping such expectations in check is a major reason why researchers in the field are moving away from the use of words like curesterilizing cure or functional cure and toward terms like “viral remission” and “post-treatment control of the virus.”

“HIV cure to me is eradication” from the body, says Ananworanich, “which is our long-term goal and not something we can hope for at the moment with the interventions we have. The more near-term goal is HIV remission.”

And as the research community saw most recently, at the 9th International AIDS Society Conference on HIV Science in Paris (IAS 2017), such viral remission is in fact possible today, at least in rare cases. Conference attendees learned of a 9-year-old South African child who was treated with ARVs for just 40 weeks after being born with HIV and has since spent more than eight years off treatment with no viral rebound.

According to Anthony S. Fauci, MD, director of the National Institute of Allergy and Infectious Diseases (NIAID), during the 2020s, researchers may indeed find ways to prompt such a state of remission in more than just a lucky few. Fauci believes that those whose early treatment (started within a few months) after contracting the virus has blunted their viral reservoirs are the most likely to benefit from such a treatment advance.


Scientists will certainly not rest on their laurels following such success. Going forward, thanks in no small part to the participants of HIV cure studies, scientific knowledge will hopefully continue to expand, yielding ever-expanding ways to liberate people living with the virus from ARV medications.


Comments

  1. Irrespective of receiving daily oral or future injectable depot therapies, these require health care visits for medication and monitoring of safety and response. If patients are treated early enough, before a lot of immune system damage has occurred, life expectancy is close to normal, as long as they remain on successful treatment. However, when patients stop therapy, virus rebounds to high levels in most patients, sometimes associated with severe illness because i have gone through this and even an increased risk of death. The aim of “cure”is ongoing but i still do believe my government made millions of ARV drugs instead of finding a cure. for ongoing therapy and monitoring. ARV alone cannot cure HIV as among the cells that are infected are very long-living CD4 memory cells and possibly other cells that act as long-term reservoirs. HIV can hide in these cells without being detected by the body’s immune system. Therefore even when ART completely blocks subsequent rounds of infection of cells, reservoirs that have been infected before therapy initiation persist and from these reservoirs HIV rebounds if therapy is stopped. “Cure” could either mean an eradication cure, which means to completely rid the body of reservoir virus or a functional HIV cure, where HIV may remain in reservoir cells but rebound to high levels is prevented after therapy interruption.Dr Itua Herbal Medicine makes me believes there is a hope for people suffering from,Parkinson's disease,Schizophrenia,Cancer,Scoliosis,Fibromyalgia,Fluoroquinolone Toxicity
    Syndrome Fibrodysplasia Ossificans Progressiva.Fatal Familial Insomnia Factor V Leiden Mutation ,Epilepsy Dupuytren's disease,Desmoplastic small-round-cell tumor Diabetes ,Coeliac disease,Creutzfeldt–Jakob disease,Cerebral Amyloid Angiopathy, Ataxia,Arthritis,Amyotrophic Lateral Sclerosis,Alzheimer's disease,Adrenocortical carcinoma.Asthma,Allergic diseases.Hiv_ Aids,Herpe ,Copd,Hpv,All Cancer Types,Diabetes,Hepatitis,I read about him online how he cure Tasha and Tara so i contacted him on drituaherbalcenter@gmail.com even talked on whatsapps +2348149277967 believe me it was easy i drank his herbal medicine for two weeks and i was cured just like that isn't Dr Itua a wonder man? Yes he is! I thank him so much so i will advise if you are suffering from one of those diseases Pls do contact him he's a nice man.

    ReplyDelete
    Replies
    1. Thanks for following up with your life story. Hopefully many people can read your comments. Thanks.

      Delete
  2. WOW WHO WILL EVE BELIEVE THAT I WILL BE THIS HAPPY TODAY, AFTER MANY YEARS OF PAIN LIVING WITH HIV VIRUS. MY NAME IS STEPHEN PETER LIVE IN UNITED KINGDOM. IT ALL HAPPEN FEW YEARS BACK WHEN I DISCOVERED THAT MY SYSTEM IS NO LONGER FUNCTIONING WELL, SO I DECIDED TO GO FOR MEDICAL CHECKUP ALL TO DISCOVERED THAT I HAVE BEEN LIVING WITH HIV POSITIVE AND I NEVER NOTICE IT FOR A VERY LONG TIME. AT THIS PARTICULAR POINT OF TIME I WANTED TO GIVE UP MY LIFE, BUT WHEN I WENT THROUGH THE INTERNET TO READ MORE ABOUT HIV, I FOUND OUT THAT THIS VIRUS IS DISGUSTING BOTH INTERNAL . GOD SO HAVE IT THAT I HARD ABOUT THIS SIMPLE WONDERFUL AND GOD SENT HERBAL DR CALLED DR AKHIGBE THE SAME DAY I WANTED TO GIVE UP EVERYTHING BECAUSE I FEEL LIFE WAS NO LONGER IMPORTANT TO ME, MANY THINGS HAPPENED BUT TO CUT THE STORY SHORT, I AM HIV NEGATIVE NOW, AND EVER SENSE I WAS CURED THERE IS NO OUTBREAK EVERYTHING HAS GONE BACK TO NORMAL AND I BELIEVE AM THE HAPPIEST PERSON ON EARTH TODAY. DR AKHIGBE NEVER ASK ME TO TESTIFY FOR HIM, I DECIDED TO DO THIS MY WAY SO THAT AS MANY THAT WILL BELIEVE AND CONTACT HIM WILL BE FREE FROM THIS DEADLY VIRUS. THIS VIRUS IS SPREADING EVERYDAY SO LET PUT OUR HANDS TOGETHER TO SAVE LIFE. BUT I KNOW MANY ARE YET TO DISCOVERED THAT THEY ARE LIVING WITH THIS VIRUS. I BELIEVE THIS IS THE MOST CRITICAL VIRUS, YOU CAN LIVE WITH IT FOR MANY YEARS AND YOU WILL NEVER NOTICE IT. WELL AM SO HAPPY TODAY ESPECIALLY WHEN MY LOST LOVE IS BACK AND WE ARE GETTING MARRIED SOON. SO MY DEAR LADIES AND GENTLEMEN LET PUT OUR HANDS TOGETHER TO SAVE AS MANY WE CAN BY SHARING THIS TESTIMONY SO THAT THOSE THAT DONT HAVE THE OPPORTUNITY TO CURE THEIR DISEASE WILL BE CURED AND BE HAPPY FOREVER, SO YOU CAN CONTACT HIM THROUGH HIS EMAIL ADDRESS, WHATSAPP NUMBER AND WEBSITE AS FOLLOWED. drrealakhigbe@gmail.com +2348142454860. https://drrealakhigbe.weebly.com

    HE CAN ALSO CURE THE FOLLOWING AND AM A LIVING TESTIMONY TO IT.
    DIABETES
    HIV
    HERPES
    CANCER
    LOW SPAMS

    CONTACT HIM TODAY AND YOUR LIFE WILL NEVER REMAIN THE SAME AGAIN, AM PROUD OF YOU DR AKHIGBE.

    ReplyDelete
  3. It’s obvious some patients with herpes are being enslaved to the antiviral and other supplementary Orthodox medicine just to help suppress the virus and not a cure. I have been with the virus since 2015 until I was introduced by a blogger who also narrated her story online on how she was cured of Genital Herpes after using Dr Sikies Herbal Medicine. This is a year and 2 weeks since I was delivered from genital Herpes. All thanks to God for using this Great herbalist to heal me. I have promised to keep telling good things about Dr Sikies. Please feel free to share Your problems with him and don’t forget to tell him I did refer you to Him. Thanks. Write him on mail Drsikies@gmail.com He deals with Alzheimer virus, Cancer, HIV, Herpes, Genital, warts, ALS, BV, UTI, Virginal infection, Genital, Wart, HPV, Hepatitis A/B, Good luck, HSV, Pregnancy, Ex back.  

    here is his website:https://drsikiesherbalcure.weebly.com 

    you can reach me via mail:anitalawson515@gmail.com

    ReplyDelete

Post a Comment

Popular posts from this blog

Q And A Forum: 20 AIDS Do's Is And Was!

Hacked To Death: Kawere Fahad 21 Years Dies From His Wounds

Q And A Forum: What is Four On Food ?